公开(公告)号：EP1183026B1

公开(公告)日：2006-07-05

申请号：EP00937743.3

申请日：2000-05-25

Applicant: ABBOTT LABORATORIES

Inventor： ALANI, Laman, A. ,  GHOSH, Soumojeet

IPC: A61K31/425 ,  A61K9/48 ,  A61P31/18

CPC classification number: A61K31/63 ,  A61K9/4858 ,  A61K31/17 ,  A61K31/427 ,  A61K31/4433 ,  A61K31/4709 ,  A61K31/472 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/5375 ,  A61K31/551 ,  Y02A50/465

Abstract: Improved pharmaceutical compositions are provided comprising one or more HIV protease inhibiting compounds having improved dissolution properties in a mixture of a fatty acid, ethanol, and water.

公开(公告)号：EP1315487A2

公开(公告)日：2003-06-04

申请号：EP01968449.7

申请日：2001-09-04

Applicant: Abbott Laboratories

Inventor： ALANI, Laman ,  GAUWITZ, Donald, P. ,  KAUL, Dilip ,  LIPARI, John, M. ,  GHOSH, Soumojeet ,  MARSH, Kennan, C. ,  WHELAN, Richard, H. ,  PETROSSIAN, Vanik, D.

IPC: A61K31/425 ,  A61K31/505 ,  A61K9/10

CPC classification number: A61K9/0095 ,  A61K31/426 ,  A61K31/513

Abstract: A flavoring system for a liquid pharmaceutical composition and pharmaceutical compositions containing such flavoring systems are disclosed. Flavoring systems of the invention include at least one sweetening agent, at least two flavored ingredients, and at least one flavor modifier selected from the group consisting of citric acid, sodium citrate, sodium chloride, and mixtures thereof. At least two of the flavored ingredients are selected from the group consisting of a vanilla flavored ingredient, a peppermint flavored ingredient, a menthol flavored ingredient, a cotton candy flavored ingredient, and mixtures thereof. The one or more sweetening agents comprise glycerin, monoammonium glycyrrhizinate, saccharin sodium, acesulfame potassium, high fructose corn syrup, and/or mixtures thereof. Pharmaceutical compositions of the invention include a flavoring system of the invention, a solvent system, and at least one pharmaceutically active agent, such as lopinavir or derivatives thereof, ritonavir or derivatives thereof, or mixtures thereof. Methods for making such liquid pharmaceutical compositions are also disclosed.

公开(公告)号：EP0942721A1

公开(公告)日：1999-09-22

申请号：EP97947510.0

申请日：1997-11-12

Applicant: Abbott Laboratories

Inventor： LIPARI, John ,  AL-RAZZAK, Laman, A. ,  GHOSH, Soumojeet ,  GAO, Rong ,  KAUL, Dilip

IPC: A61K31 ,  A61K9 ,  A61K38 ,  A61K45 ,  A61K47 ,  A61P31 ,  A61P43

CPC classification number: A61K38/55 ,  A61K9/4858 ,  A61K31/341 ,  A61K31/426 ,  A61K31/4433 ,  A61K31/47 ,  A61K31/4704 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/513 ,  A61K31/5375 ,  A61K31/551 ,  A61K38/05 ,  A61K47/10 ,  A61K47/12 ,  A61K47/26 ,  A61K47/44 ,  Y02A50/465

Abstract: A liquid pharmaceutical composition providing improved oral bioavailability is disclosed for compounds which are inhibitors of HIV protease. In particular, the composition comprises a solution in a pharmaceutically acceptable organic solvent of (a) the HIV protease inhibitor and optionally, (b) a surfactant. The composition can optionally be encapsulated in either hard gelatin capsules or soft elastic capsules (SEC).

Abstract translation: 公开了作为HIV蛋白酶抑制剂的化合物提供改善的口服生物利用度的液体药物组合物。 特别地，组合物包含在（a）HIV蛋白酶抑制剂和任选的（b）表面活性剂的药学上可接受的有机溶剂中的溶液。 该组合物可以任选地包封在硬凝胶胶囊或软弹性胶囊（SEC）中。

公开(公告)号：EP1248600B1

公开(公告)日：2008-05-14

申请号：EP00982360.0

申请日：2000-12-01

Applicant: ABBOTT LABORATORIES

Inventor： ALANI, Laman ,  GHOSH, Soumojeet

IPC: A61K9/48 ,  A61K47/10 ,  A61K47/12

CPC classification number: A61K9/4858 ,  A61K47/10 ,  A61K47/12 ,  Y02A50/465

Abstract: Improved pharmaceutical compositions are provided comprising one or more solubilized HIV protease inhibiting compounds having improved solubility properties in a medium and/or long chain fatty acid, or mixtures thereof, a pharmaceutically acceptable alcohol, and water.

公开(公告)号：EP1855683A2

公开(公告)日：2007-11-21

申请号：EP06735552.9

申请日：2006-02-21

Applicant: ABBOTT LABORATORIES

Inventor： ROSENBERG, Jöerg ,  REINHOLD, Ulrich ,  LIEPOLD, Bernd ,  BERNDL, Gunther ,  BREITENBACH, Jörg ,  ALANI, Laman ,  GHOSH, Soumojeet

IPC: A61K31/513 ,  A61K31/426 ,  A61K9/20 ,  A61K9/28

CPC classification number: A61K9/1694 ,  A61K9/1617 ,  A61K9/1635 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/2031 ,  A61K9/204 ,  A61K9/2077 ,  A61K9/2095 ,  A61K9/2866 ,  A61K31/00 ,  A61K31/426 ,  A61K31/427 ,  A61K31/513 ,  A61K47/32 ,  A61K2300/00

Abstract: The present invention provides a pharmaceutical dosage formulation, and more particularly, to a pharmaceutical dosage formulation comprising an HIV protease inhibitor.

公开(公告)号：EP1663183A2

公开(公告)日：2006-06-07

申请号：EP04816820.7

申请日：2004-08-23

Applicant: ABBOTT LABORATORIES

Inventor： ROSENBERG, Jöerg ,  REINHOLD, Ulrich ,  LIEPOLD, Bernd; ,  DERNDL, Gunther ,  BREITENBACH, Jörg ,  ALANI, Laman ,  GHOSH, Soumojeet

IPC: A61K31/00

CPC classification number: A61K31/425 ,  A61K9/146 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2027 ,  A61K9/2866

Abstract: A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50 °C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.

公开(公告)号：EP0942721B1

公开(公告)日：2003-01-22

申请号：EP97947510.0

申请日：1997-11-12

Applicant: Abbott Laboratories

Inventor： LIPARI, John ,  AL-RAZZAK, Laman, A. ,  GHOSH, Soumojeet ,  GAO, Rong ,  KAUL, Dilip

IPC: A61K31/425 ,  A61K31/535 ,  A61K31/55 ,  A61K47/10 ,  A61K47/12 ,  A61K9/48

CPC classification number: A61K38/55 ,  A61K9/4858 ,  A61K31/341 ,  A61K31/426 ,  A61K31/4433 ,  A61K31/47 ,  A61K31/4704 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/513 ,  A61K31/5375 ,  A61K31/551 ,  A61K38/05 ,  A61K47/10 ,  A61K47/12 ,  A61K47/26 ,  A61K47/44 ,  Y02A50/465

Abstract: A liquid pharmaceutical composition providing improved oral bioavailability is disclosed for compounds which are inhibitors of HIV protease. In particular, the composition comprises a solution in a pharmaceutically acceptable organic solvent of (a) the HIV protease inhibitor and optionally, (b) a surfactant. The composition can optionally be encapsulated in either hard gelatin capsules or soft elastic capsules (SEC).

公开(公告)号：EP1183026A2

公开(公告)日：2002-03-06

申请号：EP00937743.3

申请日：2000-05-25

Applicant: Abbott Laboratories

Inventor： ALANI, Laman, A. ,  GHOSH, Soumojeet

IPC: A61K31/425 ,  A61K9/48 ,  A61P31/18

CPC classification number: A61K31/63 ,  A61K9/4858 ,  A61K31/17 ,  A61K31/427 ,  A61K31/4433 ,  A61K31/4709 ,  A61K31/472 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/5375 ,  A61K31/551 ,  Y02A50/465

Abstract: Improved pharmaceutical compositions are provided comprising one or more HIV protease inhibiting compounds having improved dissolution properties in a mixture of a fatty acid, ethanol, and water.